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Abstract. Pituicytomas are a rare form of indolent neoplasms, 
which typically present with visual disturbance and hypopitu-
itarism. Complete resection by a trans-sphenoidal approach is 
the optimal treatment. Only 80 cases have been described thus 
far in the current literature and the present case is the first to 
describe the development of pituitary apoplexy in the context 
of a pituicytoma. A 77-year-old man presented with fatigue 
and clinical signs of hypogonadism and a sellar lesion was 
diagnosed at cerebral magnetic resonance imaging (MRI). A 
watch-and-wait management was initially decided and 1 year 
after the initial diagnosis, he presented with a thunderclap 
headache with images suggestive of pituitary apoplexy. A pitu-
itary adenoma was suspected and an endoscopic resection was 
decided upon the development of a visual deficit. Pathological 
analysis established the correct diagnosis of a pituicytoma. 
Pituicytomas are characterised by dense vascularisation, 
thus ischaemic and haemorrhagic events may be common. 
When confronted with a hypervascularised pituitary lesion 
demonstrating strong contrast enhancement and no abnormal 
hormonal secretion, one must maintain a high index of suspi-
cion for a pituicytoma. A wide range of differential diagnoses 
should thus be considered in the context of pituitary apoplexy.
Introduction
Pituicytomas are rare slow-growing tumours arising from 
the glial cells of the neurohypophysis and infundibulum 
(pituicytes). The histogenesis, natural history and prognosis of 
these lesions still need to be elucidated, as data in the current 
literature remain scarce.
Since the first reported case in 1955 (1), there has been a surge 
in the number of case reports and small case series describing 
this rare entity. There are no gender‑specific differences in the 
incidence of pituicytomas, and the average age of presentation 
is 50 years of age (2). No specific risk factors were identified. 
These neoplasms generally present with headaches, visual 
disturbances and manifestations of hypopituitarism (typically 
sexual dysfunction). The clinical presentation is almost iden-
tical to other more frequent sellar lesions, therefore correctly 
diagnosing these lesions can be challenging. Of about 80 cases 
described in the literature up until now (3), only one previous 
case reported an abrupt onset of clinical features and this was 
due to an intraventricular haemorrhage (4).
On imaging, even if pituicytomas present with suspicious 
radiological peculiarities, their rarity often leads them to be 
misdiagnosed for more common lesions. Surgical resection 
represents the mainstay of treatment, and this is typically via 
an endoscopic endonasal approach (5). However, complete 
resection may be challenging due to the firm consistency and 
highly vascularised nature of these tumours.
We report a novel case of a pituicytoma presenting as 
pituitary apoplexy, with the aim to advance a hypothesis to 
explain this phenomenon. To our knowledge this is the first 
reported case in the literature that describes the development 
of pituitary apoplexy in the context of a pituicytoma.
Case report
A 77-year-old man presented to the University Hospital of 
Lausanne in October 2015 with fatigue and clinical signs 
of hypogonadism. The clinical presentation was suggestive 
of hypopituitarism and endocrine tests showed an anterior 
pituitary dysfunction. Investigation with cerebral magnetic 
resonance imaging (MRI) demonstrated a sellar lesion with 
suprasellar extension and no compression of optic structures. 
He was admitted at the neurosurgical department and initial 
management consisted of hormonal replacement therapy and 
a ‘watch-and-wait’ approach. One year after his initial presen-
tation (October 2016), the patient returned to the emergency 
department with a thunderclap headache. A cerebral MRI 
demonstrated pituitary apoplexy (Fig. 1). There were no visual 
deficits on clinical examination and we decided to continue the 
regular monitoring and follow‑up. Over 6 weeks of follow‑up 
the patient started complaining of visual symptoms, secondary 
to a progressive growth of the pituitary lesion with compression 
of the optic chiasm (Fig. 2). Ophthalmological examination 
confirmed a right temporal quadrantanopia.
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The patient underwent an uncomplicated endoscopic 
endonasal transsphenoidal resection of the tumour. 
Post-operatively the patient recovered well, with the right 
temporal quadrantanopia completely resolving. Endocrine 
function remained impaired, with a persistent anterior 
hypopituitarism but no diabetes insipidus. A post-operative 
MRI confirmed complete excision of the lesion (Fig. 3), and 
follow‑up imaging at 15 months confirmed that the patient 
was still in remission.
The diagnosis of a pituicytoma was confirmed by patho-
logic examination and immunohistochemistry performed 
on four‑micron thick, formalin fixed and paraffin embedded 
sections, analysed with a Nikon Eclipse microscope and a 
Nikon DSFi1 camera (both from Nikon Corporation, Tokyo, 
Japan). Spindle-shaped cells with a fascicular growth pattern 
and heterogeneous nuclei were identified with hematoxylin 
and eosin stain (Fig. 4A and B). There was no evidence of 
atypical cellular features or mitotic figures and the detection 
of proliferation markers was performed on paraffin sections 
with anti‑Ki67 (MIB‑1; Immunotech; Beckman Coulter, 
Inc., Brea, CA, USA) with the cell count performed at high 
power (x400). Cellular proliferation resulted inferior to 1% 
(Fig. 4C). Immunohistochemical staining was performed 
through the Ventana platform and it revealed tumour cells 
positive for thyroid transcription factor-1 (TTF-1) (Fig. 4D), 
S‑100, vimentin, B‑cell lymphoma 2 (Bcl‑2) and CD56. The 
cells were negative for synaptophysin, glial fibrillary acidic 
protein (GFAP), epithelial membrane antigen (EMA), signal 
transducer and activator of transcription (STAT)6, cluster 
of differentiation 34 (CD34), Melan-A, human melanoma 
Figure 2. Sagittal (left panel) and coronal (right panel) views of a gadolinium enhanced T1-weighted cerebral magnetic resonance imaging revealing a sellar 
lesion with suprasellar extension, and intense homogeneous contrast enhancement. The pituitary stalk is not visible and the compression of the optic chiasm is 
evident (the left optic nerve is flattened just above the roof of the tumor and it is marked with an arrow head).
Figure 1. Sagittal (left panel) and coronal (right panel) views of a gadolinium enhanced T1-weighted cerebral magnetic resonance imaging. This shows a sellar 
lesion with peripheral contrast enhancement and a central hypointense core which is compatible with pituitary apoplexy (white arrow). The lesion provoked a 
sellar enlargement and presented an extension in the suprasellar space. The optic chiasm is visible immediately superior to the tumor, with no clear compres-
sion at imaging (the left optic nerve is marked with an asterisk).
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black 45 (HMB45), (tumor) protein 63 (P63), calretinin and 
neurofilament (NF). The details for each antibody and for the 
methodology used to perform immunohistochemistry were 
reported in Table I. The entire sections on the stained slides 
were evaluated. Electron microscopy was not performed.
Discussion
Pituicytomas are defined as indolent World Health Organization 
(WHO) grade 1 tumours involving the posterior lobe of the 
pituitary and/or the pituitary stalk. They are solid tumours, 
generally well circumscribed and composed of spindle cells 
derived from pituicytes (6,7).
Pituicytomas are slow growing and they may often go 
unnoticed until clinical signs and symptoms secondary to mass 
effect start to develop. These lesions are known to compress 
the pituitary gland and the optic system, thus provoking 
more frequently hypopituitarism and visual disturbance. We 
describe here the first reported case of pituitary apoplexy 
secondary to a pituicytoma. The primary goal of the manage-
ment was to mitigate the consequences of apoplexy through 
urgent hormonal substitution and to monitor for visual deficits. 
Surgical management was decided upon following the devel-
opment of a visual deficit.
Pituicytomas have similar radiological features to pituitary 
adenomas, thus distinguishing these diagnoses from one another 
Figure 4. A hematoxylin and eosin stain [initial magnification x10 in (A) and x20 in (B)] shows fascicules of spindle‑shaped cells with an absence of cellular 
atypia and mitotic figures. The proliferative index marked with the MIB‑1/Ki67 was <1% [initial magnification x10 in (C)]. Immunohistochemical staining 
was performed with the Ventana platform and it revealed tumour cells positive for TTF‑1 (Nitrogen antibody, ref 18‑0221), which is specifically expressed in 
pituicyte lineage [initial magnification x20 in (D)]. 
Figure 3. The postoperative cerebral magnetic resonance imaging with contrast confirms the complete resection of the lesion (sagittal view on the left panel 
and coronal view on the right panel). The lesion is no more present and the normal pituitary gland is visible (asterisk) in the sella. The pituitary stalk is well 
visualised in the sagittal plane (dotted arrow). 
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based on radiological imaging remains challenging. They are 
often described as sellar lesions with frequent suprasellar 
extension and sellar enlargement (and/or bone remodelling). 
They generally present as isointense lesions on T1-weighted 
MRI and the posterior lobe of the pituitary gland is gener-
ally not identifiable, while they appear as hyperintense lesions 
on T2-weighted images (2,8). T1-weighted MRI sequences 
with gadolinium contrast enhancement may prove useful in 
diagnosis, as pituicytomas may appear brighter than classical 
adenomas due to their dense vascularisation (4). A recent paper 
reports the usefulness of flow voids at the MRI to differentiate 
pituicytomas from pituitary adenomas. Flow voids represent 
signal loss due to rapidly flowing blood, and thus indirectly 
equate to increased vascularity (9). Angiography may also be 
a useful tool, with a vascular blush typical of pituicytomas (2). 
Despite these differences, radiological distinction from other 
more common sellar lesions, such as pituitary adenomas and 
meningiomas, is not always easy.
Considering this, the diagnosis of a pituicytoma strongly 
relies on pathological analysis and immunohistochemical 
investigations, as pituicytomas demonstrate a characteristic 
immunohistochemical profile with a strong positive staining for 
S-100 and TTF-1, a focal positivity for GFAP, and an absence of 
staining for synaptophysin, p53 or pericellular reticulin (6,10,11).
The mainstay of treatment for symptomatic pituicytomas 
is surgery, with gross total resection considered curative. 
Unfortunately, due to the dense vascularity and the firm 
consistency of these tumours, the extent of resection is often 
limited. Precise surgical planning is necessary, with a focus on 
the extension of the tumour itself and its radiological charac-
teristics. The development of endoscopic surgery has led to an 
endonasal approach being the preferred procedure.
Our case had a peculiar clinical presentation and we 
suggest that apoplexy was most likely due to the haemorrhagic 
transformation or to the intralesional ischemia secondary to 
the rupture or the occlusion of pathological vessels arising 
directly from the internal carotid artery or from its branches. 
We put forth the hypothesis that the incidence of pituicytoma 
apoplexy might actually be underestimated, as with pituitary 
apoplexy, surgery and tissue diagnosis is performed only in 
cases complicated by visual disturbance.
We assert that pathologists, endocrinologists and neuro-
surgeons should be mindful of pituicytoma as a possible 
differential diagnosis when dealing with pituitary apoplexy.
Table I. Antibodies used to perform the immunohistochemistry with the Ventana platform.
Antibody Clone Fabricant Reference Dilution Incubation
Antibodies that stained positively     
  TTF‑1 8G7G3/1 Invitrogen 18‑0221 1:30 32 min 37˚C
  S‑100 Polyclonal Novocastra NCL‑S100P 1:400 24 min 37˚C
  Laboratories, Ltd.
  Vimentin VIM3B4 Progen 61013 1:3,200 32 min 37˚C
  Biotechnik GmbH
  Bcl‑2 Bcl2/100/D5 Novocastra NCL‑Bcl‑2 1:30 92 min 37˚C
  Laboratories, Ltd.
  CD56/NCAM CD564 Novocastra NCL‑L‑CD56‑504 1:25 60 min 37˚C
  Laboratories, Ltd.
Antibodies that did not stain tissue     
  Synaptophysin 27G12 Novocastra NCL‑Synap‑299 1:100 32 min 37˚C
  Laboratories, Ltd.
  GFAP G‑A‑5 Sigma‑Aldrich G3893 1:15 92 min 37˚C
  EMA E29 DAKO M0613 1:100 32 min 37˚C
  STAT‑6 (S‑20) Polyclonal Santa Cruz SC‑621 1:400 60 min 37˚C
  Biotechnology, Inc.
  CD34 Qbend‑10 DAKO M7165 1:25 32 min 37˚C
  Melan‑A A‑103 DAKO M7196 1:50 32 min 37˚C
  HMB45 HMB45 DAKO M0634 1:50 32 min 37˚C
  P63 DAC‑P63 DAKO M7317 1:100 32 min 37˚C
  Calretinin CAL2 Dianova GmbH DIAL‑CAL‑250 1:20 32 min 37˚C
  NF 2F11 DAKO M0762 1:1,000 37˚C
Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA; Novocastra Laboratories, Ltd., Newcastle, UK; Progen Biotechnik GmbH, 
Heidelberg, Germany; Sigma-Aldrich, St. Louis, MO, USA; DAKO; Agilent Technologies GmbH, Waldbronn, Germany; Santa Cruz 
Biotechnology, Inc., Dallas, TX, USA; Dianova GmbH, Hamburg, Germany. Bcl-2, B-cell lymphoma 2; CD34, cluster of differentiation 34; 
CD56/NCAM, cluster of differentiation 56/neural cell adhesion molecule; EMA, epithelial membrane antigen; GFAP, glial fibrillary acidic 
protein; HMB‑45, human melanoma black 45; NF, neurofilament; P63, (tumor) protein 63; STAT‑6 (S‑20), signal transducer and activator of 
transcription 6; TTF-1, thyroid transcription factor-1.
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Recommendations and future directions. Over the last few 
years there has been substantial advancement regarding the 
definition and classification of pituicytomas (7). However, 
the histogenesis of these lesions remains controversial, and 
the natural history of progression of this disease is yet to be 
elucidated. Understanding the natural history of these tumours 
is difficult, because all of the cases described so far have been 
diagnosed retrospectively following surgical management and 
pathological confirmation.
Treatment is mainly empirical, and when gross total resec-
tion is possible, management is relatively straightforward. 
In cases where only subtotal resection is possible, the use of 
adjuvant therapies is highly debated, and there is no existing 
evidence to recommend specific management.
Further work to clarify the optimal management of patients 
with pituicytomas still needs to be undertaken, and we hope 
that future studies will help to standardise treatment strategies.
To conclude, pituicytomas are rare and indolent lesions. 
However, atypical presentations may be challenging and 
should not be underestimated. Due to the vascularised nature 
of these lesions, haemorrhagic or ischaemic events are poten-
tial serious consequences. We assert that a wider range of 
differential diagnoses should be considered when clinicians 
encounter pituitary apoplexy in the context of hypervascular-
ised pituitary lesions not associated with abnormal hormonal 
secretion.
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